Compare Heron Therapeutics Inc (HRTX) vs LYFT Inc (LYFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs LYFT Inc — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while LYFT Inc trades at $17.49 (market cap $6.53B). The key difference: LYFT Inc is far larger — about 103× Heron Therapeutics Inc's market cap, and LYFT Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | LYFT | |
|---|---|---|
Market Cap | $63.41M | $6.53B |
Sector | Health | Industrials |
52-Week High | $1.49 | $24.57 |
52-Week Low | $0.32 | $12.65 |
Enterprise Value | $161.31M | $6.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Lyft trades at $17.46, up 7.12% in the past 24 hours, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong revenue growth to $6.32 billion in 2025 and a net income of $2.84 billion, though recent Q2 2026 earnings missed estimates. Positive cash flow trends and record active riders above 30 million signal operational strength, while an ongoing legal investigation presents a headwind.
The outlook is mixed: valuation ratios like P/E of 2.54 appear attractive, and analyst consensus targets $19.17, but earnings misses and competitive pressures weigh on sentiment. Key risks include fiduciary duty investigations and moderating booking growth, requiring careful monitoring of execution against guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →
